

recombinant virus. It is estimated that evaluation of a single search of the elected group should, without undue burden, identify any art relevant to methods of immunizing a patient comprising immunogenic formulations comprising a recombinant virus encoding a tumor-associated antigen. Thus, in accordance with § 803 of the Manual of Patent Examining Procedure (MPEP), the Examiner must examine the subject matter in a single application.

However, in order to be fully responsive, Applicants hereby elect, with traverse, to prosecute the claims of Group I, Claims 1-11 drawn to a recombinant virus encoding a tumor-associated antigen, without prejudice to Applicants' right to pursue the non-elected subject matter in other applications.

Entry of the foregoing remarks is respectfully requested. An early allowance is earnestly sought.

It is estimated that no fee is necessary for filing this response. In the event a fee is required, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date February 18, 2000

Laura A. Coruzzi <sup>by: Jacqueline Bern
Reg. No. 43,492
30,742</sup>
Laura A. Coruzzi (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosure

RECEIVED
FEB 24 2000
TC 1600 MAIL ROOM